140 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp01251 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10-100 µM |
| dbacp01252 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01253 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01254 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10 µM |
| dbacp01255 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10-100 µM |
| dbacp01256 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10-100 µM |
| dbacp01257 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10-100 µM |
| dbacp01258 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10-100 µM |
| dbacp01259 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01260 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10-100 µM |
| dbacp01261 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01262 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01263 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10 µM |
| dbacp01264 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10-100 µM |
| dbacp01265 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10-100 µM |
| dbacp01266 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10-100 µM |
| dbacp01267 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10-100 µM |
| dbacp01268 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01269 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Not specified | Not specified | LC50 : 10⁻⁵ to 10⁻⁴ M |
| dbacp01270 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01271 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01272 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01273 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10-100 µM |
| dbacp01274 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01275 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01276 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01277 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01278 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01279 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Not specified | Not specified | LC50 : 10⁻⁵ to 10⁻⁴ M |
| dbacp01280 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01281 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01282 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01283 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10 µM |
| dbacp01284 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01285 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01286 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01287 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01288 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01289 | Aurein-1.1 | GLFDIIKKIAESI | Southern bell frog | Cell membrane disruption | Not specified | Not specified | Not specified | LC50 : 10⁻⁵ to 10⁻⁴ M |
| dbacp01290 | Aurein-1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Not specified | Not specified | LC50 : 10⁻⁵ to 10⁻⁴ M |
| dbacp01405 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01406 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01407 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01408 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10 µM |
| dbacp01409 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01410 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01411 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01412 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01413 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01414 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01415 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01416 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01417 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10-100 µM |
| dbacp01418 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01419 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01420 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01421 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01422 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01423 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01424 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01425 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Lung tumor cell line | Lung cancer | LC50 : 10 µM |
| dbacp01426 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Colon tumor cell line | Colon cancer | LC50 : 10-100 µM |
| dbacp01427 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Brain tumor cell line | Brain tumor | LC50 : 10 µM |
| dbacp01428 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Skin tumor cell line | Skin cancer | LC50 : 10 µM |
| dbacp01429 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01430 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01431 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp02306 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 20 µM approx. |
| dbacp02307 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 30 µM |
| dbacp02308 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 40 µM |
| dbacp02638 | Decoralin | SLLSLIRKLIT | Venom, solitary eumenine wasp | Cell membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp02744 | Dex-(KW)3 | KWKWKW | Synthetic | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | At 10 µM 60% viablity |
| dbacp02745 | Dex-(KW)3 | KWKWKW | Synthetic | Cell membrane disruption | MTT/MTS assay | MCF-7 | Breast cancer | At 10 µM 35-40% viablity |
| dbacp02972 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 41.21 µM |
| dbacp02973 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25.20 µM |
| dbacp02974 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 27.00 µM |
| dbacp02975 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 26.70 µM |
| dbacp02976 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02977 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 27.39 µM |
| dbacp02978 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 27.39 µM |
| dbacp02979 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 41.21 µM |
| dbacp02980 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25.20 µM |
| dbacp02981 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 27.00 µM |
| dbacp02982 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 26.70 µM |
| dbacp02983 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02984 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 27.39 µM |
| dbacp02985 | GA-K3 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 24.76 µM |
| dbacp02986 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 21.48 µM |
| dbacp02987 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 14.53 µM |
| dbacp02988 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.80 µM |
| dbacp02989 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 22.51 µM |
| dbacp02990 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 :29.10 µM |
| dbacp02991 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 :22.25 µM |
| dbacp02992 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 :12.55 µM |
| dbacp02993 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 21.48 µM |
| dbacp02994 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 14.53 µM |
| dbacp02995 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.8 µM |
| dbacp02996 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 22.51 µM |
| dbacp02997 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 29.10 µM |
| dbacp02998 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 22.25 µM |
| dbacp02999 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 12.55 µM |
| dbacp03000 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.88 µM |
| dbacp03001 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 20.36 µM |
| dbacp03002 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 24.63 µM |
| dbacp03003 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 24.31 µM |
| dbacp03004 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03005 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.97 µM |
| dbacp03006 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 22.06 µM |
| dbacp03007 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.88 µM |
| dbacp03008 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 20.36 µM |
| dbacp03009 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 24.63 µM |
| dbacp03010 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 24.31 µM |
| dbacp03011 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03012 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.97 µM |
| dbacp03013 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 22.06 µM |
| dbacp03014 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 :22.59 µM |
| dbacp03015 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 15.88 µM |
| dbacp03016 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.80 µM |
| dbacp03017 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 13.77 µM |
| dbacp03018 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03019 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.16 µM |
| dbacp03020 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 14.58 µM |
| dbacp03021 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.59 µM |
| dbacp03022 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-549 | Lung cancer | IC50 : 15.88 µM |
| dbacp03023 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.80 µM |
| dbacp03024 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | MKN-45 | Gastric cancer | IC50 : 13.77 µM |
| dbacp03025 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03026 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 13.16 µM |
| dbacp03027 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 14.58 µM |
| dbacp04442 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Blue-thighed frog, Australia | Cell membrane disruption | Not specified | Not found | Skin cancer | Not found |
| dbacp04453 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Blue-thighed frog, Australia | Cell membrane disruption | Not specified | Not found | Skin cancer | Not found |
| dbacp06079 | Short α-helical peptide | GIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 99% Cytotoxicity at 4µM approx. |
| dbacp06080 | Short α-helical peptide | GIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 95 % Cytotoxicity at 4µM approx. |
| dbacp06081 | Short α-helical peptide | GIIKKIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 80% Cytotoxicity at 4µM |
| dbacp06082 | Short α-helical peptide | GIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 100% Cytotoxicity at 4µM approx. |
| dbacp06083 | Short α-helical peptide | GIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 90% Cytotoxicity at 4µM approx. |
| dbacp06084 | Short α-helical peptide | GIIKKIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 70% Cytotoxicity at 5µM approx. |
| dbacp06222 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 70% Cell viability at 20 µM |
| dbacp06223 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 45% Cell viability at 30 µM |
| dbacp06224 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 30 % Cell viability at 40 µM |